Литература

1. CureSMA.org. Voice of the Patient Report. [Интернет]: http://www.curesma.org/documents/advocacy-documents/sma-voice-of-the-patient.pdf. Дата обращения: январь 2020.

2. VerhaartI E.C., Robertson A., Wilson I.J., et al. Prevalence, incidence and carrier frequency of 5q-linked spinal muscular atrophy-a literature review. Orphanet J Rare Dis. 2017; 12(1): 124.

3. Farrar M.A., Kiernan M.C. The genetics of spinal muscular atrophy: progress and challenges. Neurotherapeutics. 2015; 12(2): 290 - 302.

4. Lefebvre S., L., Reboullet Set al. Identification and characterization of a spinal muscular atrophy-determining gene. Cell. 1995 Jan 13; 80(1): 155-65.

5. Farrar M.A., Park S.B., Vucic S., et al. Emerging therapies and challenges in spinal muscular atrophy. Ann Neurol. 2017; 81(3): 355 - 368.

6. Hamilton G., Gillingwater T.H. Spinal muscular atrophy: going beyond the motorneuron. Trends Mol Med. 2013; 19(1): 40 - 50.

7. Rubin L.R. Predicting Systemic Defects in SMA. [Интернет]: http://www.smafoundation.org/wp-content/uploads/2012/03/SMA-Overview.pdf Дата обращения: январь 2020

8. Finke l.R., et al. 209th ENMC International Workshop: Outcome Measures and Clinical Trial Readiness in Spinal Muscular Atrophy 7 - 9 November 2014, Heemskerk, The Netherlands. Neuromuscul Disord. 2015; 25(7): 593 - 602.

9. Cure SMA. At School. 2016. [Интернет]: http://www.curesma.org/support-care/living-with-SMA/daily-life/at-school/. Дата просмотра: 9 января 2017 г.

10. National Organization for Rare Disorders. Werdnig-Hoffman Disease. 2012. [Интернет]: https://rarediseases.org/rare-diseases/werdnig-hoffmann-disease/. Дата обращения: январь 2017 г.

11. Iannaccone S.T. Modern management of spinal muscular atrophy. J ChildNeurol. 2007; 22(8): 974 - 978.

12. Cure SMA. Cure SMA Medical Provider Information Kit. [Интернет]: http://www.curesma.org/documents/support--care-documents/2016-sma-awareness-mpak.pdf. Дата обращения: январь 2017 г.

13. Cherry J.J., et al. Identification of novel compounds that increase SMN protein levels using an improved SMN2 reporter cell assay. J Biomol Screen. 2012; 17(4): 481 - 495.

14. Darras B.T., RoydenJones H. Jr, Ryan M.M., DeVivo D.C., eds. Neuromuscular DisordersofInfancy, Childhood, and Adolescence: A Clinician'sApproach. 2nd Ed. London, UK: Elsevier; 2015.

15. Genetics Home Reference. SMN1 gene. 2012. [Интернет]: https://ghr.nlm.nih.gov/gene/SMN1. Дата обращения: январь 2017 г.

16. Prior T.W. Perspectives and diagnostic considerations in spinal muscular atrophy. Genet Med. 2010; 12(3): 145 - 152.

17. Wang C.H., et al. Consensus statement for standard of care in spinal muscular atrophy. J Child Neurol. 2007; 22(8): 1027 - 1049.

18. National Organization for Rare Disorders. Spinal Muscular Atrophy. 2012. [Интернет]: https://rarediseases.org/rare-diseases/#causes. Дата обращения: январь 2017 г.

19. Mercuri E., Finkel R.S., Muntoni F. et al. Diagnosis and management of spinal muscular atrophy: Part 1: Recommendations for diagnosis, rehabilitation, orthopedic and nutritional care. Neuromuscul Disord. 2018 Feb; 28(2): 103 - 115.

20. Finkel R.S., Mercuri E., Meyer O.H. et al. Diagnosis and management of spinal muscular atrophy: Part 2: Pulmonary and acute care; medications, supplements and immunizations; other organ systems; and ethics. Neuromuscul Disord. 2018 Mar.; 28(3): 197 - 207.